Phaseline

Targets › INS

INS (Insulin [Cleaved into: Insulin B chain; Insulin A chain]): drug programs, companies and trials

9 programs from 9 companies in 11 trials: 5 Phase 1, 3 Phase 2, 2 Phase 4, 1 Phase 3; Metabolic and endocrine, Gastroenterology, Neurology; next expected readout Dec 2026.

Hormone secreted by pancreatic islet beta cells, that is the principal anabolic regulator of glucose, lipid, and protein metabolism and the central controller of blood glucose homeostasis. Acts by binding to and activating the insulin receptor INSR, a receptor tyrosine kinase, triggering INSR autophosphorylation and recruitment/phosphorylation of insulin receptor substrate proteins IRS1 and IRS2, which activate the…. (UniProt, P01308)

Open in Phaseline: the race on INS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Campania Luigi VanvitelliInsulin pump (CSII: Continuous subcutaneous insulin infusion)
Continuous subcutaneous delivery of rapid-acting insulin lispro as basal rate and boluses
INSPhase 4Type 1 Diabetes MellitusDec 2026
Al-Shifa Trust Eye HospitalTopical insulin eye drops
Growth factor/neurotrophic factor for corneal epithelial repair
INSPhase 4Persistent Corneal Epithelial Defect–
Elgan PharmaELGN-2112
Human insulin [rDNA]
INSPhase 3Intestinal MalabsorptionJun 2027
Gateway Institute for Brain ResearchINS-GSH
Intranasal insulin and glutathione combination
INS, GSSPhase 2Parkinson DiseaseSep 2027
Ain Shams UniversityInsulin producing stem cells
Differentiated mesenchymal stem cells producing insulin and c-peptide
INSPhase 2Stem Cells–
Shifa International HospitalInsulin Isophane Human, NPH, Pre-emptive Algorithm
Insulin replacement therapy; neutral protamine Hagedorn (NPH) formulation for intermediate
INSPhase 1Diabetes Mellitus, Type 2Jan 2027
Gan & Lee Pharmaceuticals.GZR33
Long-acting basal insulin analogue
INSPhase 1Type 1 Diabetes Mellitis–
Shanghai Jiao Tong University School of MedicineHuman insulin enteric coated capsules 16mg
Oral recombinant human insulin via enteric coating
INSPhase 1Diabete Mellitus–
Portal DiabetesPortal Insulin U-500 (PI-U500)
Insulin analog
INSPhase 1Type 1 Diabetes–

Conditions

Intestinal Malabsorption (2) Diabete Mellitus (2) Stem Cells (1) Parkinson Disease (1) Diabetes Mellitus, Type 2 (1) Type 1 Diabetes Mellitis (1) Type 1 Diabetes Mellitus (1) Persistent Corneal Epithelial Defect (1) Type 1 Diabetes (1)

Modalities

small molecule (3), protein or peptide (3), mixed (2), other (1)

Companies

Elgan Pharma (1) Ain Shams University (1) Gateway Institute for Brain Research (1) Shifa International Hospital (1) Gan & Lee Pharmaceuticals. (1) University of Campania Luigi Vanvitelli (1) Shanghai Jiao Tong University School of Medicine (1) Al-Shifa Trust Eye Hospital (1) Portal Diabetes (1)

Related targets

GSS (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.